Grant Avenue Capital has launched Helios Clinical Research
Helios Clinical Research
Helios Clinical Research is an integrated clinical site organization that partners with patients, physicians and biopharmaceutical sponsors to optimize clinical research. Its world-class clinical development team engages patients and physicians to improve the patients’ research experience, while accelerating the sponsor’s ability to obtain valuable data due to Helios’ expertise in recruiting and retaining patients. Helios’ integrated clinical research sites expedite the drug approval process by focusing on key delivery components such as study startup, patient recruiting and engagement and regulatory and quality compliance. For more information, please visit www.heliosclinical.com.
Grant Avenue Capital, a middle market healthcare-focused private equity firm, launched Helios, a new integrated clinical site organization led by world-class clinical development experts to provide greater and more equitable access to high-quality research. Helios acquired multiple clinical research sites and now operates more than 20 integrated clinical research sites that specialize in vaccines, metabolic, urology, orthopedics, gastroenterology, dermatology, oncology and broader general medicine across four states, and expects to strategically expand its footprint throughout the United States over time.
Helios is led by a world-class team of clinical development experts with decades of proven operating experience and a track record of delivering value to clinical research stakeholders, including patients, physicians and biopharma.
Tony Crisman, Managing Director in Lincoln’s Healthcare Group, commented, “Grant Avenue Capital has pulled together a top industry leadership team to build a premier integrated research platform that can truly alleviate the clinical trial execution challenges facing pharma sponsors today. We were thrilled to provide guidance and insights that were helpful to Grant Avenue Capital and their management team in building Helios.”
Grant Avenue Capital
Founded in 2019, Grant Avenue Capital is a healthcare-focused private equity firm investing alongside forward-thinking management teams seeking an experienced and innovative investor with operational insight and flexible growth capital. Based on underlying sector trends, Grant Avenue Capital pursues opportunities in the middle market across healthcare subsectors, including services, devices, pharmaceuticals and pharma services and healthcare information technology, and focuses on control buyouts, buy-and-builds, corporate carve-outs, joint-control partnership investments and special situations. In addition, the Grant Avenue Foundation supports employees and portfolio companies of Grant Avenue Capital that are actively engaged with healthcare-oriented charitable organizations. For more information, please visit www.grantave.com.
Meet our Senior Team
View More Transactions
Lincoln International advised The Beekman Group on the sale of GED Integrated Solutions to MSouth Equity Partners
Lincoln International advised Havencrest Capital Management on its majority investment in Tekton Research
Lincoln International advised Mutares on the sale of Special Melted Products to Cogne Accial Speciali, a subsidiary of Walsin Lihwa
Lincoln International advised Chequers Capital on its agreement to acquire Cheops from Indufin
Lincoln International advised Your Way Medicare on its sale to Accretive, a portfolio company of GTCR
Lincoln International advised Industrial Growth Partners on the sale of Des-Case Corporation to The Timken Company
Lincoln International advised e-Attestations on its sale of a minority stake to Keensight Capital
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.